 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| «123 |
- || Adcetris (brentuximab vedotin) / Seagen, Takeda
Clinical, P1 data, Journal: A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. (Pubmed Central) - Oct 10, 2020
P1
The combination of BV with MEC was found to be safe in patients with CD30-expressing R/R AML and warrants further study comparing this combination with the use of MEC alone in this population (ClinicalTrials.gov identifier NCT01830777).
- Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda
[VIRTUAL] Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL, NOS) Presenting With Gastrointestinal Bleeding in an HIV Patient () - Sep 15, 2020 - Abstract #ACG2020ACG_3298;
Around 30% cases of PTCL, NOS are EBV positive and the presence of EBER-ISH portends worse outcomes. Induction with anthracycline-based chemotherapy regimens along with brentuximab vedotin (an antibody-drug conjugate against CD30) for CD30+ PTCL, and early consolidation with autologous stem cell transplant (ASCT) are the cornerstones of PTCL, NOS treatment.
- Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda, Istodax (romidepsin) / Astellas, BMS
[VIRTUAL] Use of Brentuximab-ICE and Romidepsin-ICE in Relapsed/Refractory Peripheral T-Cell Lymphoma () - Sep 14, 2020 - Abstract #SOHO2020SOHO_501;
Both can improve remission rates prior to transplant with similar ORRs and CRs over 50%. More than a third of patients were able to receive transplantation.
- Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda, bendamustine / Generic mfg., Bioprofarma
[VIRTUAL] Brentuximab Vedotin and Bendamustine Combination Therapy as Salvage for Relapsed-Refractory Hodgkin Lymphoma: A Real-World Single-Center Experience () - Sep 14, 2020 - Abstract #SOHO2020SOHO_481;
More than a third of patients were able to receive transplantation. BV-Be is an effective, well-tolerated salvage treatment for patients with R/R cHL as a bridge to consolidation with HCT, and can be administered as an outpatient.
- | nirogacestat (PF-03084014) / SpringWorks Therap
Journal: Precision medicine for human cancers with Notch signaling dysregulation (Review). (Pubmed Central) - Sep 13, 2020
Small‑molecule γ‑secretase inhibitors (AL101, MRK‑560, nirogacestat and others) and antibody‑based biologics targeting Notch ligands or receptors [ABT‑165, AMG 119, rovalpituzumab tesirine (Rova‑T) and others] have been developed as investigational drugs...Phase III clinical trials of Rova‑T for patients with small‑cell lung cancer and a phase III clinical trial of nirogacestat for patients with desmoid tumors are ongoing. Integration of human intelligence, cognitive computing and explainable artificial intelligence is necessary to construct a Notch‑related knowledge‑base and optimize Notch‑targeted therapy for patients with cancer.
- || Clinical, Journal: Antibody Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. (Pubmed Central) - Sep 8, 2020
While the promise of a more targeted chemotherapy with less toxicity has not yet been realized with ADCs, improvements in technology combined with a wealth of clinical data are helping to shape the future development of ADCs. In this review we discuss the clinical and translational strategies associated with improving the therapeutic index for ADCs.
- | Journal, IO Biomarker: Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy. (Pubmed Central) - Sep 2, 2020
The resulting specific cell binding of ApEn-NK triggers higher apoptosis/death rates of lymphoma cells compared to parental NK cells. Additionally, experiments with primary human NK cells demonstrate the potential of ApEn-NK to specifically target and kill lymphoma cells, thus presenting a potential new approach for targeted immunotherapy by NK cells.
- || Adcetris (brentuximab vedotin) / Seagen, Takeda
Clinical, P2 data, Journal: A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. (Pubmed Central) - Aug 2, 2020
P2
We conclude that BV is not active as a single agent in CD30 advSM. This trial was registered at www.clinicaltrials.gov as #NCT01807598.
- Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda
[VIRTUAL] Effectiveness of brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma: A systematic review and meta-analysis (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1416;
Legal entity responsible for the study: Takeda Pharmaceuticals. Funding: Takeda Pharmaceuticals.
- || Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Clinical, Journal: A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. (Pubmed Central) - Jul 22, 2020
Patients went into remission after a median 34 (range: 12-42) months from the start of BV treatment. BV is an encouraging, well- tolerated, and effective targeted therapy especially when combined with AVD or when alternated with another targeted therapy combination, including RICE, when needed.
- || Clinical, Review, Journal: Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma. (Pubmed Central) - Jul 9, 2020
Based on a worldwide meta-analysis and multiple other retrospective studies, the antiviral combination of interferon alpha (IFN) and zidovudine (AZT) is recommended in many parts of the world in acute, chronic, and smoldering ATL whereas patients with the lymphoma subtype are treated with chemotherapy, either alone or combined with AZT/IFN. Several new agents have been approved for ATL by the Pharmaceutical and Medical Devices Agency (PMDA) after clinical trials, including an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab; an immunomodulatory agent, lenalidomide; and an anti-CD30 antibody/drug conjugate, brentuximab vedotin.
- || Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda, doxorubicin hydrochloride / Generic mfg.
Clinical, Review, Journal: Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. (Pubmed Central) - Jul 3, 2020
In addition, a randomized phase III trial ECHELON-1 reported a positive result of BV in combination with AVD (doxorubicin, vinblastine, and dacarbazine) in patients with newly diagnosed advanced-stage cHL. In this review, we summarize available data of BV for cHL and discuss the current and future role of BV in the management of cHL.
- || Adcetris (brentuximab vedotin) / Seagen, Takeda
Biomarker, Review, Journal: Biomarker-driven management strategies for peripheral T cell lymphoma. (Pubmed Central) - May 26, 2020
Targeting CD30+ PTCL with the antibody-drug conjugate brentuximab vedotin in the relapsed setting and in combination with chemotherapy in the frontline setting has improved patient survivals...Wide-ranging novel agents targeting critical intracellular pathways and tumor microenvironment are in active exploration to define clinical activities. This review summarizes PTCL-specific biomarkers which are increasingly incorporated in clinical practice to guide precision diagnosis and personalized treatment.
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Journal: Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease. (Pubmed Central) - Jul 6, 2019
The authors herein reported an 11-year-old boy with ALCL that progressed as central nervous system disease receiving intensive induction chemotherapy has achieved and maintained remission by BV and high-dose methotrexate administrated alternately. Alternate therapy with high-dose methotrexate may complement these shortcomings of BV to provide safe treatment without worsening adverse events.